Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APEX Trial: DFMO, High Dose Testosterone, and Enzalutamide in mCRPC
NCT06059118Phase 2Recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Oct 2023
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eflornithine in prostate cancer (PCa), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: PSA response rate at Cycle 1 Day 64. Started Oct 2023; status: recruiting.
02
Drugs
eflornithine
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06059118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06059118.